FEBRUARY 17TH, 2023 CONN HASTINGS MEDICINE, ONCOLOGY Researchers at the Harvard Wyss Institute and the Dana-Farber Cancer Institute have developed a new method to prepare chimeric antigen receptor-T cells (CAR-T cells) for leukemia patients that could result in more effective treatment. CAR-T cells start life as T cells that are isolated from cancer patients, are stimulated and...
by Dana-Farber Cancer Institute An artist’s depiction of a T cell. Credit: NIAID A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute investigators report at the 64th American Society of...
by Bob Yirka , Medical Xpress Immunological synapses of the Af-CAR T cells (pink) in coculture with A. fumigatus hyphae (grey). Credit: Science Translational Medicine (2022). DOI: 10.1126/scitranslmed.abh1209 An international team of researchers has developed a way to modify the CAR T engineering process to create cells that can assist in fighting fungal infections in the lungs....
by Delthia Ricks, Medical Xpress Modeling of the impact of tumor N-glycans on the targeting by CAR T cells. Left, the N-glycan decoration of tumors 1) repels CAR T cells by impeding immunological synapse formation, which tunes down transcriptional activation and overall effector functions and 2) exacerbates CAR T exhaustion by fostering inhibitory ligand–receptor pair...
by St. Jude Children’s Research Hospital Scanning electron micrograph of human T lymphocyte or T cell. Credit: NIAID/NIH Chimeric antigen receptor (CAR) T-cell therapy is immunotherapy that is making a clinical difference for patients with some blood cancers, solid tumors and chronic viral infections. Scientists at St. Jude Children’s Research Hospital have now identified how an...
August 21, 2018, Fred Hutchinson Cancer Research Center CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined. CAR-T cells with stronger signaling intensity were less...
Amostly overlooked component of CAR-T cells has a surprisingly strong effect on the cancer-fighting cells’ behavior, scientists reported on Tuesday, including in ways that might affect their safety and efficacy. The component is called the co-stimulatory domain, and the two CAR-T therapies approved last year to treat forms of leukemia and lymphoma — Yescarta and...
Pediatric patients with solid tumors may have poor quality T cells compared to patients with leukemia, and certain chemotherapies were detrimental to the T cells and their potential to become CAR T cells, according to data presented during a media preview for the AACR Annual Meeting 2018, April 14-18, in Chicago, Illinois. “The FDA approval of...
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for systematically dealing with the toxicities of these drugs. Their work, published...
